Irampanel Explained

Irampanel (INN, code name BIIR-561) is a drug which acts as a dual noncompetitive antagonist of the AMPA receptor and neuronal voltage-gated sodium channel blocker.^{[1] [2]} It was under development by Boehringer Ingelheim for the treatment of acute stroke/cerebral ischemia but never completed clinical trials for this indication.^{[3] [4]} Irampanel was also trialed, originally, for the treatment of epilepsy and pain, but these indications, too, were abandoned, and the drug was ultimately never marketed.

Notes and References

1. Feigin V . Irampanel Boehringer Ingelheim . Current Opinion in Investigational Drugs . 3 . 6 . 908–910 . June 2002 . 12137411 .
2. Wang KK, Larner SF, Robinson G, Hayes RL . Neuroprotection targets after traumatic brain injury . Current Opinion in Neurology . 19 . 6 . 514–519 . December 2006 . 17102687 . 10.1097/WCO.0b013e3280102b10 . 28119069 .
3. Book: Sharma SS, Kaundal RK . Ray A, Gulati K . Targeting Molecular Pathways in Stroke . Current Trends in Pharmacology. https://books.google.com/books?id=uB2vWIQBbxoC&pg=PA321. 1 January 2007. I. K. International Pvt Ltd. 978-81-88237-77-7. 321–.
4. Weiser T . AMPA receptor antagonists for the treatment of stroke . Current Drug Targets. CNS and Neurological Disorders . 4 . 2 . 153–159 . April 2005 . 15857300 . 10.2174/1568007053544129 .